Q-omics provides the consensus-scored ADRA2A profile across patient tissues and cancer cell-line models. ADRA2A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ADRA2A is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ADRA2A RNA expression shows 15,928 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UCEC, COAD, and BRCA as cancer lineages where ADRA2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADRA2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADRA2A survival associations across molecular data types. ADRA2A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADRA2A RNA expression–survival associations across cancer types. High ADRA2A expression shows unfavorable associations in UVM and BLCA, but favorable associations in UCEC, LUAD, HNSC and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ADRA2A RNA expression.
This table summarizes ADRA2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADRA2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADRA2A shows lower tumor expression in COAD, KICH, KIRP, BLCA, KIRC and BRCA. The COAD box plot shows higher ADRA2A RNA expression in normal versus tumor tissue (log2 FC = −2.025, t-test p < 0.001).
This table shows molecular features associated with ADRA2A in patient tissues and cancer cell lines. In patient samples, ADRA2A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ADRA2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
